Treatment Disruption Among Patients With Parkinson’s Disease With Psychosis Enrolled In US Centers For Medicare Services

October 18, 2018 Danielle Twigg

Antipsychotic (AP) treatment is used to reduce psychotic symptoms among Parkinson’s disease psychosis (PDP) patients. This study identified characteristics and factors associated with treatment disruption among US Medicare PDP patients.  Parkinson’s disease (PD) patients were identified during 2012-2015 using ICD-9 diagnosis codes from the Medicare database. PDP patients were identified after PD diagnosis and required to have two AP prescription claims (1st AP claim was index date). PDP patients were required to have 6 months of pre-index and 12 months of post-index data. During post-index, treatment disruption was defined as patients either discontinued (>30 days gap between AP fills) or were sporadic (>30 days gaps, on-off). Descriptive statistics and multivariate analysis was conducted to identify factors associated with the treatment disruptions.

Authors: Graham C, Crooke HR, Mitchell BP, Shim A

To find out more about this poster you can register to download it here after the ISPOR event.

No Previous Articles

Next Article
The Rise Of The Non-Submission – A Worrying Trend For UK Patient Access With ‘Brexit’ Approaching
The Rise Of The Non-Submission – A Worrying Trend For UK Patient Access With ‘Brexit’ Approaching